Search

Your search keyword '"Chondropoulos, Spiros"' showing total 12 results
Start Over Author "Chondropoulos, Spiros" Publication Year Range Last 10 years
12 results on '"Chondropoulos, Spiros"'

1. Effects of Chemotherapy on Aortic 18-Fluorodeoxyglucose Uptake in Patients With Hodgkin and Non-Hodgkin Lymphoma

Author

Vlachopoulos, Charalambos V., Solomou, Eirini G., Terentes Printzios, Dimitrios G., Pouli, Anastasia G., Sioni, Anastasia, Giannouli, Stavroula E., Angelopoulou, Maria K., Kafouris, Pavlos, Metaxas, Marinos G., Chondropoulos, Spiros D., Stergiou, Ioanna E., Marinakis, Theodoros P., Koutagiar, Iosif, Miliou, Antigoni A., Ioakeimidis, Nikolaos, Tsalamandris, Sotirios T., Katsi, Vasiliki, Aggeli, Constantina I., Voulgarelis, Michael, Tousoulis, Dimitrios M., Tsioufis, Constantinos, and Anagnostopoulos, Constantinos D.

Published
2023
Full Text
View/download PDF

3. Lymphoma Severity and Type Are Associated With Aortic FDG Uptake by 18F-FDG PET/CT Imaging

Author

Vlachopoulos, Charalambos V., Koutagiar, Iosif P., Georgakopoulos, Alexandros T., Pouli, Anastasia G., Sioni, Anastasia Κ., Giannouli, Stavroula Ε., Chondropoulos, Spiros D., Stergiou, Ioanna Ε., Solomou, Eirini G., Terentes-Printzios, Dimitrios G., Karakitsios, Ioannis G., Kafouris, Pavlos P., Gaitanis, Anastasios, Pianou, Nikoletta K., Petrocheilou, Aikaterini, Aggeli, Constantina I., Stroumpouli, Euaggelia, Marinakis, Theodoros P., Voulgarelis, Michael, Tousoulis, Dimitrios M., and Anagnostopoulos, Constantinos D.

Published
2020
Full Text
View/download PDF

4. Endothelial Injury Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation: Angiopetin-2 as a Novel Predictor of the Outcome and the Role of Functional Autoantibodies against Angiotensin II Type 1 and Endothelin A Receptor

Author

Vythoulkas, Dionysios, primary, Lazana, Ioanna, additional, Kroupis, Christos, additional, Gavriilaki, Eleni, additional, Konstantellos, Ioannis, additional, Bousiou, Zoi, additional, Chondropoulos, Spiros, additional, Griniezaki, Marianna, additional, Vardi, Anna, additional, Gkirkas, Konstantinos, additional, Karagiannidou, Aggeliki, additional, Batsis, Ioannis, additional, Stamouli, Maria, additional, Sakellari, Ioanna, additional, and Tsirigotis, Panagiotis, additional

Published
2023
Full Text
View/download PDF

8. Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia

Author

Tsirigotis, Panagiotis, primary, Gkirkas, Konstantinos, additional, Kitsiou, Vassiliki, additional, Chondropoulos, Spiros, additional, Athanassiades, Theofilos, additional, Thomopoulos, Thomas, additional, Tsirogianni, Alexandra, additional, Stamouli, Maria, additional, Karagiannidi, Aggeliki, additional, Siafakas, Nikolaos, additional, Pappa, Vassiliki, additional, and Nagler, Arnon, additional

Published
2021
Full Text
View/download PDF

9. Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas

Author

Stamouli, Maria Gkirkas, Konstantinos Karagiannidi, Aggeliki Iliakis, Theodoros Chondropoulos, Spiros Thomopoulos, Thomas Nikolaou, Vassiliki Pappa, Vassiliki Papadavid, Evangelia Tsirigotis, Panagiotis

Abstract

The prognosis of patients with mycosis fungoides (MF) and Sezary Syndrome (SS) varies greatly, from near normal life expectancy in patients with early stage, to a median survival of less than 2 years for those diagnosed with advanced stage disease. Initial response to treatment is almost always followed by relapse and, finally, most of patients enter a phase of advanced multi-drug resistant disease with a short life expectancy after multiple lines of treatment. Allogeneic stem cell transplantation (allo-SCT) is usually limited to patients with advanced disease resistant to multiple treatments. Retrospective registry-based studies have shown increased Non-relapse Mortality (NRM) rates in patients with poor performance status, as well as in patients treated with myeloablative conditioning regimens. Another major limitation of allo-SCT is the increased relapse rate which occurs in nearly 50% of the cases, and is probably due to the fact that only heavily pretreated patients with advanced disease are referred for allo-SCT. Due to the paucity of data, the ideal conditioning regimen which will provide the maximum therapeutic benefit without the cost of increased NRM is not currently known. In this article we present our experience with a novel regimen in the treatment of patients with advanced MF/SS.

Published
2021

11. Serum Cytokine Profile in Patients with Septic Shock/Severe Sepsis and Thrombocytopenia

Author

Tsirigotis, Panagiotis, primary, Gkirkas, Konstantinos, additional, Chondropoulos, Spiros, additional, Papassotiriou, Ioannis, additional, Bartzeliotou, Anastasia, additional, Economopoulou, Christina, additional, Atta, Maria, additional, Papanikolaou, Nikolaos, additional, Ioannidou, Dikea-Eleni, additional, Vasilatou, Diamantina, additional, Papageorgiou, Sotirios G, additional, Stamouli, Maria, additional, Pappa, Vassiliki, additional, and Dimopoulou, Ioanna, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results